| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| Amulet | Patients will have nonvalvular atrial fibrillation. This irregular beating of the heart leads to a slowing of the blood flow in the upper chambers of the heart. In the left upper chamber, there is a small pouch called the left atrial appendage (LAA). Slowing of blood, especially in the LAA, may cause blood clots to form. Blood clots can move from the LAA and travel to the brain, causing a stroke or transient ischemic attack (TIA), also called a mini-stroke. These blood clots can also travel to other parts of the body and block blood vessels. The Amulet device could be beneficial because it may lower the chance of a new blood clot forming and moving from the heart’s LAA to other parts of your body. | Heart & Vascular | Structural Heart Disease |
| Aveir DR | The objective for this study is to confirm the safety and effectiveness of the Aveir LP (Leadless Pacemaker) System in a subject population indicated for a dual chamber pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
| Complete TAVR | The purpose of this study is to determine whether restoring blood flow to all blocked or narrowed arteries via percutaneous coronary intervention (PCI) using coronary stents is better than treating the coronary artery disease (CAD) with medications in patients with CAD who had successful transcatheter aortic value replacement (TAVR) with a balloon expandable heart valve. The study will also compare measurements of hemodynamics (blood flow and blood pressure) that are taken during on-table procedures (TAVR and PCI) with those taken by echocardiography (heart ultrasound). | Heart & Vascular | Cardiovascular Disease |
| Iocyte Faraday STEMI drug | The purpose of this study is to evaluate the efficacy and safety of the study drug vs placebo in subjects with an anterior ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). | Heart & Vascular | Heart Failure |
| Node X | Participants must have participated in a prior study with the investigational drug etripamil (the NODE-301, NODE-302, or NODE-303 study). The study is being done to determine the safety of etripamil 70 mg for the treatment of multiple episodes of PSVT in an at-home setting. | Heart & Vascular | Cardiac Arrhythmia |
| PPP/PAN/PSR | This study is a registry study. The purpose is to collect information over time about how Medtronic products are working and/or the outcome of the treatment. The registry will be used to support post-market surveillance activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research. The registry is not an experimental clinical study. | Heart & Vascular | Cardiac Arrhythmia |
| Rethink Reflux Registry | The purpose of this study is to gather information about how the LINX device works over an extended period in people with GERD (gastric esophageal reflux disease). | Surgery | GERD (Gastro Esophageal Reflux Disease) |
| Arrhythmia Detection After Myocardial Infarction (AID-MI) | This study will evaluate the use of an insertable cardiac monitor in patients following an acute myocardial infarction (heart attack) to determine if cardiac monitoring results in more rhythm-related findings that change management compared to standard of care post heart attack management in patients who do not receive the insertable cardiac monitor. | Heart & Vascular | Cardiac Arrhythmia |
| CREST 2 LOE | Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE) | Heart & Vascular | Carotid Stenosis |
| Real AF | Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry | Heart & Vascular | Atrial Fibrillation |
| V-Inception | A randomized, controlled, multicenter, open-label trial comparing a hospital post-discharge care pathway involving aggressive LDL-C management that includes inclisiran with usual care versus usual care alone in patients with a recent acute coronary syndrome (VICTORION-INCEPTION) | Heart & Vascular | Lipid Management |
| EA2176 | The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic anal cancer. | Cancer | Metastic Anal |
| S1925 | The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months. | Cancer | Hematology |
| A031803 | The purpose of this study is to determine the effectiveness of intravesical gemcitabine in combination with prembrolizumab. Patients must have been diagnosed with invasive bladder and already received chemo. | Cancer | Bladder |
| AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL1231 | A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) | Childhood Cancers | Leukemia |
| AALL1521 | A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2 Rearranged and/ or JAK Pathway-Mutant Acute Lymphoblastic Leukemia | Childhood Cancers | Leukemia |
| Acoustic Diagnosis of Gastroesophageal Reflux Disease | Baby/Child | Reflux Disease | |
| ANBL1232 | Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma | Childhood Cancers | Blastoma |
| APEC14B1 EveryChild | A Registry, Eligibility Screening, Biology and Outcome Study | Childhood Cancers | Registry |
| Bayer ON-TRK | The purpose of this study is to learn about the effectiveness of Vitrakvi in patients with TRK Fusion cancer. You must have a advanced solid tumor with a NTRK gene fusion. | Cancer | All tumor types |
| Champion AF | The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. | Heart & Vascular | Atrial Fibrillation |
| COG-AALL05B1 | Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens | Childhood Cancers | Leukemia |
| COG-AALL1331 | Risk Stratified Randomized Phase lll Testing of blinatumomab (IND#117467, NCS#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) | Childhood Cancers | Leukemia |
| COG-ACNS0332 | Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients | Childhood Cancers | Blastoma |
| COG-ACNS0831 | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years | Childhood Cancers | Glioma |
| COG-AEWS07B1 | A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens | Childhood Cancers | Sarcoma |
| COG-AHEP0731 | Treatment of Children with All Stages of Hepatoblastoma | Childhood Cancers | Blastoma |
| COG-AHOD1331 | A randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents | Childhood Cancers | Lymphoma |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.